Events PET Scan Radiation 
AuntMinnie
OCTOBER 2, 2024
tesla MRI AI body composition analysis Cardiac PET Cryo/thermoablation CT colonography Genicular artery embolization Hyperpolarized xenon-129 MRI PET/MRI Photon-counting CT Radiomics Theranostics Whole-body MRI screening Image of the Year 3D PET/MR image. PET scans predict patient response to Pluvicto.
AuntMinnie
MARCH 26, 2024
The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
MAY 31, 2023
Additionally, Omni Legend offers a streamlined, simple solution that helps enable technologists to increase efficiency, enhance patient care, and reduce potential radiation exposure to medical staff vii.” iii] Based on orders data of GE HealthCare PET/CT systems since 2010. [iv] iv] Omni Legend 32 cm has up to 2.2 ix Mehranian, A.,
AuntMinnie
JUNE 20, 2024
The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
Imaging Technology
MAY 30, 2023
This event marks a major milestone in the expansion of Blue Earth Diagnostics’ robust prostate cancer portfolio. Results demonstrated high detection rates (% positive PET scans) even at low PSA levels. Gauden , D.Phil., Chief Executive Officer of Blue Earth Diagnostics. The adverse reactions reported in ≥0.4%
Imaging Technology
MAY 2, 2023
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.
AuntMinnie
JULY 8, 2024
and included limited single and cumulative radiation doses. Three grade 3 CAM-H2 treatment emergent adverse events (TEAE) were reported in three patients who had a previous history of thrombocytopenia, lung disease, or liver disease, with no grade 4 or 5 adverse events reported.
Expert insights. Personalized for you.
137 
Let's personalize your content